Dr. Apter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
256 Bunn Dr
Suite 6
Princeton, NJ 08540Phone+1 609-921-3555Fax+1 609-921-3620
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Psychiatry, 1976 - 1979
University of the WitwatersrandClass of 1974
Certifications & Licensure
IL State Medical License 1977 - Present
NY State Medical License 1983 - Present
NJ State Medical License 1979 - 2025- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder Start of enrollment: 2008 Sep 01
- Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease Start of enrollment: 2008 Oct 01
- PRC-063 in Adolescent ADHD Start of enrollment: 2014 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 52 citationsPlacebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.Michael H. Kronig, Jeffrey T. Apter, Gregory M. Asnis, Alexander Bystritsky, George C. Curtis
Journal of Clinical Psychopharmacology. 1999-04-01 - 133 citationsInterruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial.David Michelson, Maurizio Fava, Jay D. Amsterdam, Jeffrey T. Apter, Peter Londborg
The British Journal of Psychiatry. 2000-04-01 - 62 citationsCombined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial.Rena Cooper-Kazaz, Jeffrey T. Apter, Revital Cohen, Leonid Karagichev, Said Muhammed-Moussa
Archives of General Psychiatry. 2007-06-01
Press Mentions
Biotechnology Brings New Approach and Fresh Hope to Alzheimer’s ResearchNovember 22nd, 2021
Here Comes a Whole New Approach to Battling Alzheimer’s, and New Jersey Will Play a Lead RoleApril 22nd, 2019
NJ-Based, Minority Woman-Owned Firm Tapped to Promote Alzheimer’s Disease Drug TrialJanuary 10th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
